A pre-commercial biotechnology firm specializing in rare disease oncology treatments using its Tribrid® antibody-drug conjugate platform to advance promising clinical candidates.
Investors may be attracted by the potential for significant value creation if any of Travere's late-stage clinical candidates receive FDA approval, as a single successful rare disease product can generate substantial revenue. The company's positive operating cash flow and growing gross profit suggest improving financial discipline that could support future commercialization efforts without immediate dilution. Strategic partnerships with large pharmaceutical entities provide validation of the technology platform and potential access to broader distribution networks upon approval.
The absence of any approved products leaves the company vulnerable to total revenue shortfalls if clinical trials fail, which is a common occurrence in late-stage biotechnology development. With a retained earnings deficit exceeding $1.4B and high general and administrative expenses relative to revenue, the company remains cash-burn heavy despite recent operational improvements. The stock price is highly sensitive to binary events like trial readouts, leading to extreme volatility that may not be suitable for risk-averse investors.
Travere Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for rare diseases and oncology, leveraging its proprietary Tribrid® platform to optimize antibody-drug conjugates (ADCs). The company operates primarily in the United States but serves global markets through strategic collaborations and licensing agreements. Its pipeline targets high-unmet-need patient populations with a focus on advancing candidates from discovery through clinical development.
Despite reporting a net loss of $25.5M in 2025, the company demonstrated significant operational efficiency with cash flow from operations turning positive at $37.8M, indicating strong cost controls relative to its revenue generation. The gross profit margin expanded substantially in 2025 compared to previous years, reflecting a strategic shift toward monetizing licensed assets rather than solely relying on internal R&D burn. However, the company continues to rely heavily on financing activities with net cash flow from investing showing volatility, suggesting active management of its asset portfolio.
The rare disease oncology sector offers significant opportunities for specialized biotechnology firms targeting conditions with limited treatment options and high willingness-to-pay from patients and payers. However, the industry is characterized by long development timelines, expensive clinical trials, and a highly competitive landscape where only a few companies can sustain R&D costs until product approval. Success in this space requires robust intellectual property portfolios and strategic collaborations to mitigate the high financial risk inherent in drug discovery.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $212.0M | $145.2M | $233.2M | $490.7M |
| Cost of Revenue | $7.6M | $11.4M | $7.7M | $10.3M |
| Gross Profit | $204.4M | $133.8M | $225.4M | $480.4M |
| Operating Expenses | $471.0M | $521.9M | $549.3M | $543.2M |
| Operating Income | $-266.6M | $-388.1M | $-323.8M | $-62.8M |
| R&D | $7.5M | — | — | — |
| G&A | $220.2M | $265.5M | $264.1M | $337.2M |
| Stock-Based Comp | $39.2M | $44.2M | $36.9M | $44.9M |
| D&A | $33.1M | $38.5M | $43.6M | $60.7M |
| Depreciation | $2.1M | $2.2M | $1.8M | $1.5M |
| Amortization | $31.0M | $36.3M | $41.7M | $59.2M |
| Other OpEx | $243.3M | $256.4M | $285.1M | $206.0M |
| Non-Operating Income | $-11.6M | $12.0M | $3.3M | $13.6M |
| Interest Expense | $11.3M | $11.3M | — | — |
| Interest Income | $6.3M | $21.8M | $17.8M | $12.7M |
| Pre-Tax Income | $-278.2M | $-376.1M | $-320.5M | $-49.3M |
| Income Tax | $313.0K | $223.0K | $120.0K | $988.0K |
| Continuing Ops | $-278.5M | $-376.3M | $-320.6M | $-50.3M |
| Discontinued Ops | $0 | $264.9M | $-915.0K | $24.7M |
| Net Income | $-278.5M | $-111.4M | $-321.5M | $-25.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-278.5M | $-111.4M | $-321.5M | $-25.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $486.4M | $616.8M | $416.7M | $437.6M |
| Cash & Equivalents | $61.7M | $58.2M | $58.5M | $93.0M |
| Accounts Receivable | $16.6M | $21.2M | $27.1M | $80.1M |
| Inventory | $6.9M | $9.4M | $6.2M | $36.2M |
| Prepaid Expenses | $12.6M | $19.3M | $12.7M | $28.8M |
| Other Current Assets | $388.6M | $508.7M | $312.2M | $199.5M |
| Long-Term Assets | $186.1M | $172.1M | $177.4M | $167.6M |
| PP&E (Net) | $9.0M | $7.5M | $5.3M | $4.0M |
| Intangibles | $145.0M | $104.4M | $104.0M | $113.9M |
| Goodwill | $900.0K | $800.0K | $800.0K | — |
| Operating Leases | $21.0M | $18.1M | $14.3M | $10.6M |
| Other LT Assets | $10.2M | $41.4M | $53.0M | $39.2M |
| Total Assets | $672.6M | $788.9M | $594.1M | $605.2M |
| Current Liabilities | $142.2M | $177.9M | $200.8M | $159.9M |
| Accounts Payable | $17.3M | $41.7M | $23.5M | $24.8M |
| Current Leases | $4.4M | $4.9M | $5.4M | $5.9M |
| Deferred Revenue | $12.0M | $7.1M | $2.8M | — |
| Other Current Liab | $12.7M | $5.2M | $83.0M | $3.2M |
| Long-Term Liabilities | $487.6M | $410.2M | $334.3M | $330.5M |
| LT Operating Leases | $27.5M | $22.6M | $17.2M | $11.1M |
| Other LT Liab | $449.1M | $385.7M | $317.1M | $319.3M |
| Total Liabilities | $629.7M | $588.1M | $535.0M | $490.4M |
| Shareholders' Equity | $42.9M | $200.8M | $59.1M | $114.8M |
| Paid-In Capital | $1.06B | $1.33B | $1.51B | $1.59B |
| Retained Earnings | $-1.01B | $-1.13B | $-1.45B | $-1.47B |
| AOCI | $-2.9M | $-1.5M | $-80.0K | $-1.2M |
| Total L&E | $672.6M | $788.9M | $594.1M | $605.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-278.5M | $-111.4M | $-321.5M | $-25.5M |
| Non-Cash Adjustments | $74.2M | $-254.9M | $120.2M | $17.5M |
| Working Capital Changes | $17.9M | $86.3M | $-36.1M | $45.9M |
| Cash from Operations | $-186.3M | $-280.0M | $-237.5M | $37.8M |
| Capital Expenditures | $191.0K | $668.0K | — | — |
| Cash from Investing | $-32.6M | $55.8M | $99.3M | $27.9M |
| Cash from Financing | $117.6M | $218.8M | $139.4M | $-33.5M |
| FX Effect | $-2.8M | $2.0M | $-913.0K | $2.3M |
| Net Change in Cash | $-104.1M | $-3.5M | $359.0K | $34.5M |
| Beginning Cash | $165.8M | $61.7M | $58.2M | $58.5M |
| Ending Cash | $61.7M | $58.2M | $58.5M | $93.0M |
The company's revenue is primarily driven by milestone payments and royalties from strategic licensing partnerships with major pharmaceutical companies, such as the collaboration for TVT-1009 targeting rare cancers. Additional segments include government grants and reimbursements for research activities, as well as potential future revenues from commercial sales once key assets enter the market.
The company faces significant commercialization risk as it has no approved products, making future revenue entirely dependent on successful regulatory approvals and execution of clinical trials. High operating expenses related to research and development, combined with a substantial retained earnings deficit, indicate vulnerability if key asset development fails or funding dries up. The biotechnology sector is subject to volatile stock prices driven by binary clinical trial outcomes and shifting payer reimbursement policies for rare disease therapies.
The company utilizes its proprietary Tribrid® technology to create highly potent antibody-drug conjugates that achieve superior tumor penetration and reduced off-target toxicity compared to conventional ADCs. Strong intellectual property protection across its platform and a robust pipeline of late-stage clinical candidates provide a defensible moat in the rare disease oncology space. A lean organizational structure and strategic cash management allow for efficient progression of multiple assets simultaneously.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.